Search ARM

Celyad is a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies. The company’s lead clinical program is focused on the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) and is currently evaluating the first-in-class autologous (personalized) NKG2D-based CAR-T therapy, CYAD-01 and next-generation candidate, CYAD-02, in multiple Phase 1 clinical trials. Celyad is also developing a non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy referred to as CYAD-101, which is currently in Phase 1 development for the treatment of patients with metastatic colorectal cancer (mCRC). The company is also advancing next-generation, allogeneic CAR-T candidates using its short hairpin RNA (shRNA) technology platform, led by CYAD-211, a BCMA targeting CAR-T therapy for the treatment of multiple myeloma (MM).

Contact Celyad
info@ceylad.com
Visit Website